These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36403368)

  • 1. Advanced-stage CRC incidence patterns following the phased implementation of the CRC screening programme in the Netherlands.
    Breekveldt ECH; Toes-Zoutendijk E; Spaander MCW; van de Schootbrugge-Vandermeer HJ; van Vuuren AJ; van Kemenade FJ; Ramakers CRB; Dekker E; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
    Eur J Cancer; 2023 Jan; 178():60-67. PubMed ID: 36403368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study.
    Breekveldt ECH; Lansdorp-Vogelaar I; Toes-Zoutendijk E; Spaander MCW; van Vuuren AJ; van Kemenade FJ; Ramakers CRB; Dekker E; Nagtegaal ID; Krul MF; Kok NFM; Kuhlmann KFD; Vink GR; van Leerdam ME; Elferink MAG;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):60-68. PubMed ID: 34822762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in diagnostic activity in general practice and findings for individuals invited to the danish screening programme for colorectal cancer: a population-based cohort study.
    Juul JS; Andersen B; Laurberg S; Carlsen AH; Olesen F; Vedsted P
    Scand J Prim Health Care; 2018 Sep; 36(3):281-290. PubMed ID: 29929415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of delayed screening invitations on screen-detected and interval cancers in the Dutch colorectal cancer screening programme: individual-level data analysis.
    Toes-Zoutendijk E; de Jonge L; van Iersel CA; Spaander MCW; van Vuuren AJ; van Kemenade F; Ramakers CR; Dekker E; Nagetaal ID; van Leerdam ME; Lansdorp-Vogelaar I
    Gut; 2023 Jul; 72(7):1319-1325. PubMed ID: 37076272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population-based screening for colorectal cancer using an immunochemical faecal occult blood test: a comparison of two invitation strategies.
    Van Roosbroeck S; Hoeck S; Van Hal G
    Cancer Epidemiol; 2012 Oct; 36(5):e317-24. PubMed ID: 22560885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How a faecal immunochemical test screening programme changes annual colorectal cancer incidence rates: an Italian intention-to-screen study.
    Bucchi L; Mancini S; Baldacchini F; Ravaioli A; Giuliani O; Vattiato R; Zamagni F; Giorgi Rossi P; Campari C; Canuti D; Di Felice E; Sassoli de Bianchi P; Ferretti S; Bertozzi N; Biggeri A; Falcini F;
    Br J Cancer; 2022 Aug; 127(3):541-548. PubMed ID: 35444286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic indicator of the impact of colorectal cancer screening programmes on incidence rates.
    Zorzi M; Zappa M;
    Gut; 2020 Feb; 69(2):311-316. PubMed ID: 31040168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Faecal immunochemical test after negative colonoscopy may reduce the risk of incident colorectal cancer in a population-based screening programme.
    Peng SM; Hsu WF; Wang YW; Lin LJ; Yen AM; Chen LS; Lee YC; Wu MS; Chen TH; Chiu HM
    Gut; 2021 Jul; 70(7):1318-1324. PubMed ID: 32989019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colorectal cancer mortality after randomized implementation of FIT-based screening - a nationwide cohort study.
    Njor SH; Larsen MB; Søborg B; Andersen B
    J Med Screen; 2022 Dec; 29(4):241-248. PubMed ID: 35635233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized colorectal cancer screening: study protocol of a mixed-methods study on the effectiveness of tailored intervals based on prior f-Hb concentration in a fit-based colorectal cancer screening program (PERFECT-FIT).
    Breekveldt ECH; Toes-Zoutendijk E; de Jonge L; Spaander MCW; Dekker E; van Kemenade FJ; van Vuuren AJ; Ramakers CRB; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
    BMC Gastroenterol; 2023 Feb; 23(1):45. PubMed ID: 36814185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of a Six-Year Existing Screening Programme Using the Faecal Immunochemical Test in Flanders (Belgium) on Colorectal Cancer Incidence, Mortality and Survival: A Population-Based Study.
    Tran TN; Hoeck S; De Schutter H; Janssens S; Peeters M; Van Hal G
    Int J Environ Res Public Health; 2023 Jan; 20(2):. PubMed ID: 36674409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of Colorectal Cancer Screening in Detecting Earlier-Stage Disease-A Nationwide Cohort Study in Denmark.
    Larsen MB; Njor S; Ingeholm P; Andersen B
    Gastroenterology; 2018 Jul; 155(1):99-106. PubMed ID: 29626451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential for prevention: a cohort study of colonoscopies and removal of adenomas in a FIT-based colorectal cancer screening programme.
    Larsen MB; Njor SH; Jensen TM; Ingeholm P; Andersen B
    Scand J Gastroenterol; 2019 Aug; 54(8):1008-1014. PubMed ID: 31397598
    [No Abstract]   [Full Text] [Related]  

  • 15. Interval cancers in a population-based screening program for colorectal cancer with gender-specific cut-off levels for fecal immunochemical test.
    Ribbing Wilén H; Saraste D; Blom J
    J Med Screen; 2022 Sep; 29(3):156-165. PubMed ID: 35257615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.
    Wisse PHA; de Klaver W; van Wifferen F; Meiqari L; Bierkens M; Greuter MJE; Carvalho B; van Leerdam ME; Spaander MCW; Dekker E; Coupé VMH; de Wit M; Meijer GA
    BMC Cancer; 2022 Dec; 22(1):1299. PubMed ID: 36503495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interval cancers after negative immunochemical test compared to screen and non-responders' detected cancers in Slovenian colorectal cancer screening programme.
    Mlakar DN; Bric TK; Škrjanec AL; Krajc M
    Radiol Oncol; 2018 Jul; 52(4):413-421. PubMed ID: 30511936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Attendance to an Organized Fecal Immunochemical Test Screening Program on the Risk of Colorectal Cancer: An Observational Cohort Study.
    Baldacchini F; Bucchi L; Giuliani O; Mancini S; Ravaioli A; Vattiato R; Zamagni F; Giorgi Rossi P; Mangone L; Campari C; Sassatelli R; Trande P; Esposito P; Rossi F; Carrozzi G; Triossi O; Fabbri C; Strocchi E; Giovanardi M; Canuti D; Sassoli de Bianchi P; Ferretti S; Falcini F;
    Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2373-2382. PubMed ID: 35144023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variation in changes in the incidence of colorectal cancer by age and association with screening uptake: an observational study.
    Clark GR; Anderson AS; Godfrey TG; Strachan JA; Fraser CG; Steele RJ
    BMJ Open; 2020 Sep; 10(9):e037925. PubMed ID: 32963068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colorectal cancer screening by guaiac faecal occult blood test in France: Evaluation of the programme two years after launching.
    Leuraud K; Jezewski-Serra D; Viguier J; Salines E
    Cancer Epidemiol; 2013 Dec; 37(6):959-67. PubMed ID: 24035240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.